Test Data Show 90% Accuracy on Finding Pancreatic Cyst Malignancy

Article

The numbers are in on studies of a new diagnostic called PancraGen's ability to distinguish pancreatic malignancies from other findings in pancreatic cysts.

The numbers are in on studies of a new diagnostic called PancraGen’s ability to distinguish pancreatic malignancies from other findings in pancreatic cysts.

The test has 90% accuracy in stratifying patients for risk of pancreatic cancer with better accuracy than standard guideline-recommended tests alone, PDI Inc. announced at the American College of Gastroenterology Scientific meeting in Honolulu.

The data were presented in poster abstracts at the conference.

Under American College of Gastroenterology guideline criteria for managing cyst lesions, there is a less than 50% sensitivity for malignancy. As a result, many patients whose cysts are not indicative of cancer have unnecessary surgery. The test is a DNA-based molecular diagnostic that analyzes cyst fluid.

More than 120,000 such cysts are detected annually in the US usually with imaging studies of other organs that find them incidentally since the cysts are asymptomatic.

“All pancreatic cysts except those with clear cytological malignancy are ideal candidates for testing with PancraGen,” the company said.

Under other detection methodologies, up to 80% of surgeries on pancreatic cyst patients are potentially unnecessary, it noted. PDI, Inc is based in Parsippany, NJ. Interpace Diagnostics is a subsidiary of PDI.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.